tetano
Editor, Senior Moderator
Mod Rheumatol Case Rep
. 2024 Aug 3:rxae042.
doi: 10.1093/mrcr/rxae042. Online ahead of print. New-onset of giant cell arteritis with ischemic optic neuropathy following the seventh-dose of COVID-19 mRNA vaccination: A case report and literature review
Shin-Ichiro Ohmura[SUP] 1 [/SUP], Haruka Yonezawa[SUP] 1 [/SUP], Toshitaka Yukishima[SUP] 1 [/SUP], Yuko Gohto[SUP] 2 [/SUP], Akira Obana[SUP] 2 [/SUP]
Affiliations
Coronavirus disease (COVID-19) vaccines have demonstrated excellent efficacy in reducing the morbidity and severity of the disease. However, some patients have been reported to develop systemic rheumatic diseases, such as rheumatoid arthritis, myocarditis, Guillain-Barre syndrome, and giant cell arteritis (GCA) following COVID-19 vaccination. We present a case of GCA with ischemic optic neuropathy following COVID-19 mRNA vaccination. A 73-year-old woman developed headache, myalgia, scalp tenderness, and jaw claudication 4 days after her seventh dose of the vaccination; she also developed severe visual disturbances 1 month after the vaccination. The blood examination tests showed an increased serum C-reactive protein level and erythrocyte sedimentation rate. The echogram for the temporal artery showed a halo sign. Ophthalmic examination revealed ischemic optic neuropathy in both eyes. The patient was treated with a high-dose glucocorticoid and tocilizumab under the diagnosis of GCA with ischemic optic neuropathy, obtaining mild improvement of the symptoms. This report underscores the need for clinical vigilance and further data collection regarding GCA cases after COVID-19 vaccination.
Keywords: COVID-19; Coronavirus disease; giant cell arteritis; ischemic optic neuropathy; vaccine.
. 2024 Aug 3:rxae042.
doi: 10.1093/mrcr/rxae042. Online ahead of print. New-onset of giant cell arteritis with ischemic optic neuropathy following the seventh-dose of COVID-19 mRNA vaccination: A case report and literature review
Shin-Ichiro Ohmura[SUP] 1 [/SUP], Haruka Yonezawa[SUP] 1 [/SUP], Toshitaka Yukishima[SUP] 1 [/SUP], Yuko Gohto[SUP] 2 [/SUP], Akira Obana[SUP] 2 [/SUP]
Affiliations
- PMID: 39096515
- DOI: 10.1093/mrcr/rxae042
Coronavirus disease (COVID-19) vaccines have demonstrated excellent efficacy in reducing the morbidity and severity of the disease. However, some patients have been reported to develop systemic rheumatic diseases, such as rheumatoid arthritis, myocarditis, Guillain-Barre syndrome, and giant cell arteritis (GCA) following COVID-19 vaccination. We present a case of GCA with ischemic optic neuropathy following COVID-19 mRNA vaccination. A 73-year-old woman developed headache, myalgia, scalp tenderness, and jaw claudication 4 days after her seventh dose of the vaccination; she also developed severe visual disturbances 1 month after the vaccination. The blood examination tests showed an increased serum C-reactive protein level and erythrocyte sedimentation rate. The echogram for the temporal artery showed a halo sign. Ophthalmic examination revealed ischemic optic neuropathy in both eyes. The patient was treated with a high-dose glucocorticoid and tocilizumab under the diagnosis of GCA with ischemic optic neuropathy, obtaining mild improvement of the symptoms. This report underscores the need for clinical vigilance and further data collection regarding GCA cases after COVID-19 vaccination.
Keywords: COVID-19; Coronavirus disease; giant cell arteritis; ischemic optic neuropathy; vaccine.